Literature DB >> 22361268

Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects.

A G Tzioufas1, P G Vlachoyiannopoulos.   

Abstract

The 11th International Symposium for Sjogren's syndrome was held in Athens, Greece in September 2011. This symposia is part of a long series of meetings that have attempted to meet the needs of both scientists and physicians in improving the healthcare of their patients with Sjogren's syndrome. Sjogren's syndrome affects almost 0.5% of the general population and is second only to rheumatoid arthritis amongst the systemic autoimmune diseases. More importantly, it has daily implications for the millions of sufferers around the world. The goal of this meeting, which included nearly 200 abstracts and invited lectures, was to address the critical needs in the clinical practice of Sjogren's syndrome. This volume is a composite of select papers that were presented at this meeting and attempts to provide a critical overview of clinical and basic science. The volume includes a variety of themes and, importantly, raises issues that are still unresolved but which are important in our future diagnostic and therapeutic efforts.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22361268     DOI: 10.1016/j.jaut.2012.01.006

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  15 in total

Review 1.  [Ultrasound diagnostics in Sjögren's syndrome].

Authors:  V S Schäfer; W A Schmidt
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

2.  Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  Tetsuya Akaishi; Toshiyuki Takahashi; Kazuo Fujihara; Tatsuro Misu; Juichi Fujimori; Yoshiki Takai; Shuhei Nishiyama; Michiaki Abe; Tadashi Ishii; Masashi Aoki; Ichiro Nakashima
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 4.849

3.  Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis.

Authors:  V Hauk; L Fraccaroli; E Grasso; A Eimon; R Ramhorst; O Hubscher; C Pérez Leirós
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

Review 4.  Autoimmunity in 2012.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

5.  Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.

Authors:  Lingli Dong; Yu Chen; Yasufumi Masaki; Toshiro Okazaki; Hisanori Umehara
Journal:  Curr Immunol Rev       Date:  2013-02

6.  B-cell and T-cell quantification in minor salivary glands in primary Sjögren's syndrome: development and validation of a pixel-based digital procedure.

Authors:  Sebastian Costa; Sacha Schutz; Divi Cornec; Arnaud Uguen; Isabelle Quintin-Roué; Agnès Lesourd; Jean-Marie Berthelot; Eric Hachulla; Pierre-Yves Hatron; Vincent Goeb; Olivier Vittecoq; Jacques Olivier Pers; Pascale Marcorelles; Alain Saraux; Valérie Devauchelle-Pensec
Journal:  Arthritis Res Ther       Date:  2016-01-20       Impact factor: 5.156

7.  Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability.

Authors:  Sandrine Jousse-Joulin; Emmanuel Nowak; Divi Cornec; Jackie Brown; Andrew Carr; Marina Carotti; Benjamin Fisher; Joel Fradin; Alojzija Hocevar; Malin V Jonsson; Nicoletta Luciano; Vera Milic; John Rout; Elke Theander; Aaltje Stel; Hendrika Bootsma; Arjan Vissink; Chiara Baldini; Alan Baer; Wan Fai Ng; Simon Bowman; Zarrin Alavi; Alain Saraux; Valérie Devauchelle-Pensec
Journal:  RMD Open       Date:  2017-06-09

8.  Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.

Authors:  Raphaèle Seror; Gaétane Nocturne; Thierry Lazure; Houria Hendel-Chavez; Frédéric Desmoulins; Rakiba Belkhir; Philippe Ravaud; Mohcine Benbijja; Vichnou Poirier-Colame; Yacine Taoufik; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2015-09-04       Impact factor: 5.156

9.  Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

Authors:  Francesco Carubbi; Paola Cipriani; Alessandra Marrelli; Paola Benedetto; Piero Ruscitti; Onorina Berardicurti; Ilenia Pantano; Vasiliki Liakouli; Saverio Alvaro; Alessia Alunno; Antonio Manzo; Francesco Ciccia; Roberto Gerli; Giovanni Triolo; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2013-10-30       Impact factor: 5.156

Review 10.  Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis.

Authors:  Francine Bertolais do Valle Souza; Gustavo José Martiniano Porfírio; Brenda Nazaré Gomes Andriolo; Julia Vajda de Albuquerque; Virginia Fernandes Moça Trevisani
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.